Business Context and Reporting Period
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for kidney and metabolic diseases using its proprietary Compass platform. This Form 10-Q covers the quarterly period ended June 30, 2026. The company is classified as an Emerging Growth Company (EGC) and a non-accelerated filer. As of August 5, 2026, there were 55,549,168 shares of common stock outstanding.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2026 | Six Months Ended June 30, 2026 | As of June 30, 2026 |
|---|---|---|---|
| License Revenue | $0 | $20.0 million | N/A |
| Total Operating Expenses | $48.0 million | $94.6 million | N/A |
| Net Loss | $(44.7) million | $(68.9) million | N/A |
| Net Loss Per Share (Basic & Diluted) | $(0.76) | $(1.22) | N/A |
| Cash, Cash Equivalents, and Marketable Securities | N/A | N/A | $494.9 million |
| Total Debt (Term Loan) | N/A | N/A | $39.0 million (carrying value) |
| Accumulated Deficit | N/A | N/A | $(558.5) million |
Material Changes vs. Prior Period
- Revenue: The company recognized $20.0 million in license revenue for the six months ended June 30, 2026, driven by a clinical development milestone payment from Shionogi regarding the MZE001 program. No revenue was recognized in the comparable period in 2025.
- Operating Expenses: Total operating expenses increased by $22.7 million (32%) for the six-month period compared to the prior year. Research and Development (R&D) expenses rose by $13.4 million, primarily due to increased headcount, higher stock-based compensation, and progression of the MZE829 clinical program. General and Administrative (G&A) expenses increased by $9.3 million, largely due to personnel costs and professional services.
- Financing Activities: The company completed an underwritten registered offering in April 2026, raising approximately $144.6 million in net proceeds. Additionally, the company funded an initial term loan of $40.0 million under a new Hercules Loan Agreement in February 2026.
- Net Loss: Net loss for the six months ended June 30, 2026, was $68.9 million, compared to $66.5 million in the prior year period. The increase in loss was offset by the $20.0 million in milestone revenue and higher interest income from increased cash balances.
Guidance, Outlook, and Risks
- Clinical Progress:
- MZE829: Positive topline Phase 2 proof-of-concept data was announced in March 2026 showing a reduction in proteinuria. The company plans to continue enrollment and report additional data in late 2026 or early 2027, with a pivotal trial planned for the first half of 2027.
- MZE782: Phase 2 proof-of-concept trial in patients with Phenylketonuria (PKU) initiated in August 2026, with topline data expected in 2027. A Phase 2 trial for Chronic Kidney Disease (CKD) is planned for the first half of 2027.
- Liquidity: Management believes existing cash, cash equivalents, and marketable securities ($494.9 million) are sufficient to fund operations for at least one year from the filing date. The company has access to up to $160.0 million in additional term loan tranches under the Hercules facility and a $200.0 million at-the-market (ATM) equity offering program.
- Risks and Contingencies:
- Debt Covenants: The Hercules Loan Agreement includes financial covenants requiring the maintenance of unrestricted cash and cash equivalents at specific percentages of the outstanding loan amount, unless market capitalization thresholds are met.
- Partnership Termination: In August 2026, the company received notice from Neurocrine Biosciences of its intent to terminate the Neurocrine License Agreement effective November 2026. Management does not expect this to materially impact previously recognized revenue.
- Regulatory and Development Risks: As a clinical-stage company, the business faces significant risks regarding the success of clinical trials, regulatory approvals, and the ability to raise additional capital on favorable terms.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $494.9 million cash position against the projected burn rate for the upcoming Phase 2 and pivotal trials.
- Debt Covenants: Monitor compliance with the Hercules Loan Agreement's liquidity covenants and the impact of the $39.0 million debt on future financing flexibility.
- Clinical Milestones: Track the timing and results of the MZE829 Phase 2 data readout (late 2026/early 2027) and the initiation of the MZE782 CKD trial (H1 2027).
- Partnership Revenue: Assess the potential for future milestone payments from Shionogi and the impact of the Neurocrine termination on the pipeline.
- Capital Raises: Monitor the utilization of the $200.0 million ATM facility and the potential dilution from future equity offerings.